Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04804007 · ClinicalTrials.gov registry record · Phase 2
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
A Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, sponsored by Nabil Adra.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT04804007 is a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor that is actively recruiting participants, run by Nabil Adra. The registered enrollment target is 64 participants, below the 344-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04804007, a Phase 2 study of Germ Cell Tumor and Ovarian Germ Cell Tumor, is actively recruiting participants, sponsored by Nabil Adra.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
Conditions Studied
Interventions
- DRUG Etoposide
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04804007
The ClinicalTrials.gov registry entry for NCT04804007 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 344-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (81% lower). The listed sponsor is Nabil Adra, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Etoposide is the first listed.
NCT04804007 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04804007 about?
NCT04804007 is a clinical study titled "Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT". This is an open label randomized phase II trial of maintenance oral etoposide vs. observation in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
What is the current status of trial NCT04804007?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2021-03-03. Estimated completion is 2028-12.
What conditions does trial NCT04804007 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Ovarian Germ Cell Tumor, Non-seminomatous Germ Cell Tumor.
What interventions are being tested in trial NCT04804007?
The interventions under investigation include: Etoposide (DRUG).
Who is sponsoring clinical trial NCT04804007?
This trial is sponsored by Nabil Adra, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04804007 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
RECRUITING · Phase 2
-
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
ACTIVE NOT RECRUITING · Phase 2
-
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.